The combination of sitagliptin and metformin is indicated in patients who are not adequately controlled on metformin or sitagliptin alone or in patients already taking both agents
Our team can explain eligibility, documentation needs, next steps, and whether this program may be appropriate based on your medical evaluation
The FDA states these trials are conducted under widely varying conditions and, therefore, rates of side effects may not reflect the rates observed in practice. In practice, there are many variables that could affect side effects, including health conditions and drug interactions
In the end, 31.6% of tirzepatide recipients achieved 25% body weight reduction compared to 16.1% in the semaglutide group
These are substantial absolute weight reductions, far exceeding what lifestyle-only approaches typically achieve. 6 Participants receiving tirzepatide were: 1.3 more likely to lose 10% 1.6 more likely to lose 15% 1.8 more likely to lose 20% 2.0 more likely to lose 25% compared to semaglutide
In the 24-week study, 9% of patients receiving Januvia 100 mg and 21% of patients receiving placebo required rescue therapy
